Join
Live feed
·
PRReleasevia Quantisnow
Sesen Bio Inc. logo

Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)

ByQuantisnow·Wall Street's wire, on your screen.
SESN· Sesen Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SESN (Sesen Bio Inc.) and more on Quantisnow.